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Mutant Cu, Zn Superoxide Dismutase that Causes Motoneuron
Degeneration Is Present in Mitochondria in the CNS
Cynthia M. J. Higgins,1 Cheolwha Jung,1 Hongliu Ding,1 and Zuoshang Xu,1,2,3
1Department of Biochemistry and Molecular Pharmacology, 2Cell Biology, and 3Neuroscience Program, University of
Massachusetts Medical School, Worcester, Massachusetts 01655
Mutations in Cu, Zn superoxide dismutase (SOD1) cause a
fraction of amyotrophic lateral sclerosis (ALS), which involves
motoneuron degeneration, paralysis, and death. An acquired
activity by mutant SOD1 is responsible for the cellular toxicity,
but how mutant SOD1 kills motoneurons is unclear. In trans-
genic mouse models of ALS, mitochondrial degeneration oc-
curs early, before disease onset, raising the question of how
mutant SOD1 damages mitochondria. Here we investigate the
intracellular localization of SOD1 in the CNS to determine
whether SOD1 is present in mitochondria, where it could di-
rectly damage this organelle. We show that endogenous mouse
SOD1, wild-type human, and mutant human SOD1 (G93A),
when expressed as transgenes, are colocalized with mitochon-
dria in spinal cord by immunofluorescence confocal micros-
copy. By immunoelectron microscopy, we show that SOD1 is
present within mitochondria at similar concentrations as in the
cytoplasm. Thus SOD1, in addition to being a cytosolic en-
zyme, is present inside mitochondria in the CNS.
Key words: motor neuron disease; neurodegenerative dis-
ease; neurodegeneration; spinal cord; ALS; aging
Superoxide dismutase (SOD1) is a 17 kDa protein, known to be
present in cytoplasm as a homodimer (Fridovich, 1986). Its func-
tion is superoxide dismutation. Mutations in SOD1 cause a frac-
tion of amyotrophic lateral sclerosis (ALS), a fatal neurodegen-
erative disease in which motoneurons degenerate, resulting in
paralysis and death (Brown, 1995). Several experiments have
demonstrated that mutant SOD1 causes motoneuron degenera-
tion by gaining a toxic property, rather than a loss of superoxide
dismutation function (Dal Canto and Gurney, 1995; Ripps et al.,
1995; Wong et al., 1995). There are two major hypotheses regard-
ing the toxic properties gained by the mutant SOD1. The first
suggests that mutant SOD1 damages cells by producing peroxyni-
trite (Estevez et al., 1999), whereas the second proposes that
mutant SOD1 damages cells by its enhanced peroxidase activity
(Wiedau-Pazos et al., 1996; Yim et al., 1996, 1997). The validity
of either hypothesis remains to be proven (Xu, 2000).
An important question in understanding the mechanism of
motoneuron degeneration is what the cellular target for this
toxicity is, or what is the cellular pathway that leads eventually to
cell death. Previous studies have observed mitochondrial vacuo-
lation in transgenic mice expressing mutant SOD1 (Dal Canto
and Gurney, 1995; Wong et al., 1995), and the peak of this
vacuolation correlates with the onset of clinical disease (Kong
and Xu, 1998). Furthermore, widespread mitochondrial abnor-
malities are present before the peak vacuolation and clinical
disease (Kong and Xu, 1998). The evidence suggests that mito-
chondrial damage is an early step in the mutant SOD1-induced
motoneuron degeneration pathway, raising the question of how
mutant SOD1 damages mitochondria.
SOD1 has been thought to be a cytoplasmic protein (Crapo et
al., 1992). Some studies, however, have suggested the presence of
a small fraction of the total cellular SOD1 in the intermembrane
space of liver mitochondria (Weisiger and Fridovich, 1973; Tyler,
1975), although this has been controversial (Geller and Winge,
1982). In light of the new evidence that mitochondria are dam-
aged in mice expressing mutant SOD1 and develop ALS, we
revisited this issue and investigated whether mutant SOD1 is
associated with mitochondria in the CNS. We present double
immunofluorescence and ultrastructural evidence that a fraction
of endogenous mouse SOD1 and transgenic wild-type and mutant
human SOD1 in the mouse is present within mitochondria in the
CNS. Thus, mutant SOD1 could exert its toxicity directly on
mitochondria, leading to mitochondrial damage and onset of
motoneuron degeneration.
MATERIALS AND METHODS
Transgenic mice. Two transgenic mouse lines (The Jackson Laboratory,
Bar Harbor, ME) were used. One expresses human SOD1 mutant G93A
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(C57BL/6J-TgN(SOD1-G93A)1Gur dl) (G93A mice), and the other ex-
presses wild-type human SOD1 (WS mice) (Gurney et al., 1994). Non-
transgenic littermates of G93A transgenic mice were used as wild-type
controls (WT mice). All transgenic mice were identified using PCR
according to Gurney et al. (1994). Mice were maintained at the University
of Massachusetts Medical School animal facility according to the guidelines
set forth by the Institutional Animal Care and Use Committee.
Double immunofluorescence. Mice were killed by decapitation under
anesthesia, and spinal cords were dissected quickly. Lumbar and cervical
spinal cords were cut out, frozen immediately in OCT freezing media
(Sakura, Torrance, CA) on dry ice, and stored at 80°C. Eight micro-
meter sections were cut using a cryostat and mounted on slides treated
with Vectabond (Vector Laboratories, Burlingame, CA). The slides were
incubated in PBS at room temperature for 30 min, followed by fixation
with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.5, for 10 min.
After washing, the sections were doubly stained with anti-SOD1 (Pardo
et al., 1995) and anti-cytochrome C oxidase subunit 1 (COX1) antibodies
(Molecular Probes, Eugene, OR) according the protocol described pre-
viously (Kong et al., 1998; Levine et al., 1999). The stained sections were
examined and digitized using a confocal microscope (TCS-SP; Leica,
Mannheim, Germany). Imaging analysis and three-dimensional recon-
struction were conducted using MetaMorph (Universal Imaging Corpo-
ration, West Chester, PA).
Immunoelectron microscopy. Mice (60- to 80-d-old) were perfused
under anesthesia with fixative (4% paraformaldehyde, 0.1% glutaralde-
hyde in 0.1 M phosphate buffer, pH 7.5). Lumbar spinal cords from fixed
mice were dissected out and dehydrated through an ethanol series to
100% ethanol and embedded in hard grade LR White resin (Electron
Microscopy Sciences, Fort Washington, PA) by polymerization overnight
at 60°C. Sixty-five nanometer sections were cut from the embedded tissue
using a Reichert-Jung Ultracut E microtome and collected onto gold
grids (200 mesh) (SPI Inc., Westchester, PA). Sections on grids were
processed for immunogold electron microscopy according to recommen-
dations by the manufacturer of the gold-conjugated antibodies (Amer-
sham Biosciences, Piscataway, NJ) with some modification. Sections were
etched in 0.1N HCl for 5 min, rinsed three times for 5 min each in TBS
(in mM: 25 Tris, 140 NaCl, and 2.7 KCl, pH 8.0), placed in blocking
buffer for 30 min (0.1% gelatin, 1% normal goat serum, and 0.3%
Triton-X-100 in TBS), placed in primary antibody for 2 hr at room
temperature, rinsed three times for 5 min each in TBS, placed in
gold-conjugated secondary antibodies (10 nm gold anti-mouse and 5 nm
gold anti-rabbit) for 1 hr, rinsed three times in TBS, fixed in 2%
glutaraldehyde, rinsed three times in TBS, rinsed in water, stained with
Reynold’s lead citrate followed by aqueous 2% uranyl acetate, and dried
on filter paper. The following antibodies and sera were used: normal
rabbit serum (Vector Laboratories), rabbit polyclonal anti-SOD1 (Pardo
et al., 1995), a second rabbit polyclonal anti-SOD1 (Biodesign, Saco,
ME), mouse monoclonals against cytochrome oxidase subunit 1 (COX1)
and against COX subunit 4 (Molecular Probes), and rabbit polyclonal
anti-neurofilament light chain (Xu et al., 1993). All antibodies and serum
were used at a 1:10 dilution.
The stained sections were viewed and photographed using a Philips
CM10 transmission electron microscope. The negatives were digitized,
and immunogold density was determined using MetaMorph software as
follows. The number of gold particles were counted inside and outside
mitochondria and then normalized to the areas of mitochondria and
nonmitochondria, respectively. Myelin and extracellular areas are ex-
cluded from the measurement. However, it is not practical to exclude all
other cytoplasmic organelles because the identity and the boundary of
these organelles are often not unequivocal. Therefore, organelles other
than mitochondria are included as nonmitochondrial area. Results were
summarized as the average per mitochondrion and average per extra-
mitochondrial space in a micrograph.
RESULTS
To determine whether SOD1 is associated with mitochondria, we
examined whether SOD1 was present in mitochondrial fractions
from mouse brain homogenates. SOD1 was detected in the mi-
tochondrial fractions from WT mice and in increasing amounts
from mice expressing wild-type human SOD1 (WS) and mice
expressing mutant SOD1 (G93A) (data not shown). This result
gave us preliminary evidence that SOD1 was associated with
mitochondria in the CNS as was shown for liver (Weisiger and
Fridovich, 1973; Tyler, 1975). As in the previous reports using
liver, it was impossible to purify mitochondria using biochemical
fractionation to the extent that other organelles could be elimi-
nated as sources of SOD1 (Geller and Winge, 1982). Therefore,
we decided to resolve this issue using morphological means.
Double immunofluorescence staining was performed on spinal
cord sections from G93A mice using anti-SOD1 and anti-COX1
(mitochondrial marker) antibodies. Because of the high concen-
tration of cytoplasmic SOD1 (which generates a high SOD1
staining background), it was difficult to demonstrate colocaliza-
tion of SOD1 and COX1 signals in fixed mouse spinal cords. To
reduce the level of extraorganelle cytosolic SOD1, unfixed frozen
spinal cord sections from G93A mice were incubated in PBS for
30 min to allow unassociated SOD1 to diffuse away. Sections were
then fixed with 4% paraformaldehyde and stained using routine
double immunofluorescent staining method.
Widespread overlapping signals from mitochondria and SOD1
were observed (Fig. 1A) (notice the abundant yellow structures in
the right panel; some examples are pointed out by arrows). All
COX1-immunoreactive structures overlap with SOD1-positive
structures, although many SOD1-positive structures are negative
for COX1 (Fig. 1A). Because mitochondria are small, it was
possible that overlaps seen in the XY dimensions were not real in
the Z dimension. To rule out this possibility, serial sections were
recorded using a confocal microscope and reconstructed in three
dimensions. In all cases, the overlaps between the COX1 and
SOD1 signals were confirmed (Fig. 1B,C) (also see supplemental
videos at www.jneurosci.org). The same results were obtained in
digitonin-permeablized cultured pheochromocytoma cell line and
HeLa cells when their endogenous SOD1 was detected by double
SOD1 and COX1 immunofluorescence (data not shown).
To determine whether the SOD1 is inside or attached to the
outside of mitochondria, SOD1 was further localized at the
ultrastructural level using immunoelectron microscopy (Fig. 2).
Lumbar spinal cord sections from the three different mice (G93A,
WS, and WT) were stained by immunogold for SOD1 (small
particles) and mitochondrial enzyme cytochrome oxidase (large
particles). Mitochondria were identified by their characteristic
structure and by their positive staining for cytochrome oxidase
(Fig. 2A,C,E, large particles). All mitochondria are positively
stained for SOD1 (Fig. 2A,C,E, small particles). Far more small
particles are present in G93A and WS spinal cords than those in
the WT spinal cord, consistent with overexpression of SOD1 in
the transgenic animals. Very few, if any, small particles are
present in the matrix (Fig. 2A,C, asterisks), indicating that SOD1
is unlikely to be in the matrix compartment. Sections incubated
with a second anti-SOD1 antibody (Biodesign) yielded the same
staining pattern (data not shown). In control staining in which an
anti-neurofilament subunit NF-L antibody was substituted for the
anti-SOD1 antibody, small particles are largely confined to the
cytoplasm and are segregated from the large particles that reside
inside mitochondria (Fig. 2B,D,F). In two additional controls in
which the sections were incubated with nonimmune rabbit serum
followed by the secondary antibody or the sections were incubated
with the secondary antibody alone, only sparse background par-
ticles were occasionally detected (data not shown).
To estimate the relative concentration of SOD1 inside mito-
chondria when compared with that in the intracellular space
outside of mitochondria, we counted the small gold particles
inside and outside mitochondria. These counts confirm that the
gold particle densities representing SOD1 in WS and G93A mice
are several fold higher than those in the WT mice (Fig. 3). The
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density of SOD1 in mitochondria is slightly higher inside mito-
chondria than that in the extramitochondrial cytosolic space,
although this difference is only significant in G93A mice (Fig. 3)
( p  0.02 using two-tailed Student’s t test). In contrast to a high
density of SOD1 both inside and outside of mitochondria, staining
with a rabbit polyclonal antibody against neurofilament light chain
shows a high density only outside of mitochondria and essentially
no counts of gold particles within mitochondria (Fig. 3).
Figure 1. Double immunofluorescent staining of spinal cord sections from G93A mice using anti-COX1 ( green) and SOD1 (red) antibodies. A,
Low-magnification view of an area covering part of the ventral column motor axon exit zone. The panel on the right shows the superimposition of COX1
and SOD1 staining. B, C, High-magnification view of two small groups of mitochondria. The three panels on the right illustrate the same mitochondria
as shown in the lef t panels except that they are rotated 40 and 90° in B and C, respectively. The numbers mark the same mitochondria viewed from the
two different angles. The bottom two panels are superimposition of the top two green and red panels (for a complete three-dimensional view, see the
supplemental videos at www.jneurosci.org).
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DISCUSSION
This study presents immunofluorescence and ultrastructural evi-
dence that a fraction of wild-type and mutated SOD1 is localized
within mitochondria in the CNS. First, double immunofluores-
cence and three-dimensional reconstruction reveal that all mito-
chondria are colocalized with SOD1 signals in the spinal cord of
mutant SOD1 transgenic mice (Fig. 1). Second, abundant SOD1
signals are detected within the mitochondria by immuno-EM
(Fig. 2). In addition, quantification of immunogold staining
against SOD1 reveals that the gold particle density inside mito-
chondria is similar to that in the cytosol outside of mitochondria,
suggesting that SOD1 concentration inside mitochondria is at
comparable levels with the cytosol.
The presence of SOD1 in mitochondria was reported by several
previous studies, which suggested that SOD1 is in the intermem-
brane space (Weisiger and Fridovich, 1973; Peeters-Joris et al.,
1975; Tyler, 1975; Henry et al., 1980). However, doubts were
raised because a later study found that SOD1 in mitochondrial
Figure 2. Immunogold localization of SOD1 in the spinal cord from G93A (A, B), WS (C, D), and WT (E, F ) mice. A, C, E, Sections reacted with rabbit
polyclonal anti-SOD1 (5 nm particles) and mouse monoclonals against COX subunit 1 and 4 (10 nm particles). B, D, F, Sections incubated with rabbit
polyclonal anti-neurofilament light chain (5 nm particles) and mouse anti-COX1 and 4 (10 nm particles). Scale bars, 100 nm. Each asterisk indicates
significantly less than the concentration within mitochondria ( p  0.02 using two-tailed Student’s t test).
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fractions could be accounted for by contamination with lysosomes
(Geller and Winge, 1982). Further doubts were raised when some
laboratories reported the presence of SOD1 in peroxisomes
(Keller et al., 1991; Dhaunsi et al., 1992; Wanders and Denis,
1992). These controversies are derived from the difficulty in
making pure mitochondria completely devoid of contamination
by other cellular organelles. Our current approach circumvented
this difficulty by double immunofluorescence and immunogold
staining on prefixed CNS spinal cords and cultured cells. The
results demonstrate that a fraction of SOD1 is inside mitochon-
dria in the CNS.
In conjunction with previous data showing that mitochondria
are an early target for damage by mutant SOD1 in transgenic
mice (Dal Canto and Gurney, 1995; Wong et al., 1995; Kong and
Xu, 1998), these results raise the possibility that mutant SOD1
might damage mitochondria directly. This is supported by mor-
phological observation in human ALS, which showed abundant
abnormal mitochondria (Hirano et al., 1984; Nakano and Hirano,
1987). Although not all transgenic mouse models for ALS (e.g.,
G85R) (Bruijn et al., 1997) exhibit morphologically abnormal
mitochondria, functional abnormalities cannot be ruled out. In-
deed, mutant SOD1, when introduced into cells, causes mito-
chondrial dysfunction (Carri et al., 1997; Kruman et al., 1999).
Using cybrid technology, Swerdlow et al. (1998) demonstrated
mitochondrial dysfunction in platelet cells isolated from humans
with sporadic ALS. The efficacy of creatine treatment in slowing
the disease progression in mice expressing mutant SOD1 further
supports that mitochondrial damage plays a role in mutant SOD1-
induced motoneuron degeneration (Klivenyi et al., 1999).
Our results agree with recently published data demonstrating
that SOD1 is in the intermembrane space of yeast mitochondria
(Sturtz et al. 2001) and a report showing that mutant SOD1 was
associated with vacuolated mitochondria in the CNS of ALS
transgenic mice (Jaarsma et al., 2001). Our data show that endog-
enous SOD1 in wild-type mice is in morphologically normal
mitochondria, and that both normal and ALS-causing mutant
human SOD1 in transgenic mice are in mitochondria, probably at
concentrations similar to that in the cytoplasm. Although our
antibody does not distinguish between mouse and human SOD1
(it detects both), it is unlikely that normal and mutant SOD1 are
segregated. This is because when either is overexpressed, signal
intensity is proportionally increased in both the mitochondrial
and cytoplasmic compartments (Fig. 3).
Mitochondria are known to be a major, and probably the most
predominant, source of oxidative free radicals in cells, and thus,
may provide a fertile environment for the effects of the mutant
SOD1 toxicity. For instance, if either of the two major hypotheses
regarding the nature of the mutant SOD1 toxicity (see introduc-
tory remarks) is correct, mitochondria could provide abundant
substrates for the mutant SOD1 to further generate toxic free
radicals, which in turn damage mitochondria from within. Some
possible downstream effects have been reported in literature,
including impairment in energy metabolism (Hatazawa et al.,
1988), elevated oxidative stress (Beal, 1998; Hall et al., 1998),
increased sensitivity to excitotoxicity (Ikonomidou and Turski,
1996; Rothstein, 1996; Bittigau and Ikonomidou, 1997), deficient
axonal transport (Cleveland, 1999), and deregulation of apoptosis
(Kostic et al., 1997; Li et al., 2000). Of particular interest is a
recent observation that the vulnerability to excitotoxicity in mo-
toneurons appears to be selectively enhanced when mitochondrial
function is impaired (Kaal et al., 2000). Taken together, our
results indicate that mitochondrial damage is an important area
of investigation in the causes of ALS.
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